Updated factsThe financing was necessary to survive and has been announced but not yet closed.
The financing is dilutive with significant added share count and low priced warrants
There have been no announced NXO revenue contracts beyond the Pristine Surgical deal which if Pristine begins to earn revenues 4Q/2022 means NXO gets cash in say mid 23 if any is owed
The Selten deal does not appear to have closed
ALL ELSE IS NOISE